Vijey Aanandhi M, Meha Rachel John
Vijey Aanandhi M1*, Meha Rachel John2
1Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels University (VISTAS), Chennai - 600 117, Tamilnadu, India
2Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels University (VISTAS), Chennai -600 117, Tamil Nadu, India.
Volume - 10,
Issue - 8,
Year - 2017
Enteral nutrition has been known to bring about reduction in infectious complications in post major abdominal surgery. Previous systematic reviews and meta-analysis have suggested that immune nutrition in critically ill have been associated with reduced hospital stay, infection rate and inflammatory response. Glutamine is considered an essential amino acid during stress and critical illness. Parenteral glutamine supplementation in critically ill patients has been shown to improve survival rate and minimise infectious complications, costs and hospital length-of-stay. The purpose of this article is to provide a narrativereview of the current evidence and trials of enteral and parenteral glutamine supplementation in multipletrauma patients. A search in PubMed and EMBASE was conducted and relevant papers that investigated the effect of enteral or parenteral glutamine supplementation in patients with multiple trauma were reviewed. Although recent nutritional guidelines recommend that glutamine supplementation should be considered in these patients, further well-designed trials are required to provide a confirmed conclusion. Due to the inconclusive results of enteral glutamine supplementation trials in patients receiving enteral nutrition, future trials should focus on intravenous glutamine supplementation in patients requiring enteral nutrition and on major clinical outcome measures (e.g. mortality rate, infectious complications).
Cite this article:
Vijey Aanandhi M, Meha Rachel John. Role of Glutamine Supplementation in Critically ill patients: A Narrative Review. Research J. Pharm. and Tech. 2017; 10(8): 2801-2808. doi: 10.5958/0974-360X.2017.00496.6